BioPharma Resources

Company · TAK

Takeda

Includes drugs filed under related and acquired sponsor names. Trials are searched under: Takeda; Shire; Millennium Pharmaceuticals, Inc..

Last checked: Nov 19, 2026Source: Drugs@FDA, ClinicalTrials.gov

NDAs and BLAs

63

40 still marketed

Novel approvals

33

Approvals since 2021

22

Originals and new uses

Phase 3 trials

545

Registered, any status

Trials by phase

All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.

Recent approvals

Originals and efficacy supplements, newest first.

  • Mimrylo approved NovelPriority reviewOrphanAug 28, 2026
  • Orzeyful approved NovelPriority reviewOrphanAug 5, 2026
  • Livtencity new use OrphanNov 21, 2025
  • Iclusig new use OrphanOct 10, 2025
  • Motegrity new use Jul 10, 2025
  • Entyvio approved Apr 18, 2024
  • Iclusig new use Priority reviewOrphanMar 19, 2024
  • Eohilia approved Breakthrough therapyPriority reviewOrphanFeb 9, 2024
  • Fruzaqla approved NovelPriority reviewNov 8, 2023
  • Entyvio approved Sep 27, 2023

Drugs in development (18)

Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.

Open in pipeline
  • ZasocitinibTAK- 279, NDI-034858Phase 317 trials

    Takeda · Plaque Psoriasis, Psoriatic Arthritis, Crohn's Disease

  • ElriterceptTAK-226, KER-050Phase 36 trials

    Takeda · Myelodysplastic Syndromes, Myelofibrosis, Anemia

  • TDVTAK-003, Tetravalent Dengue VaccinePhase 35 trials

    Takeda · Dengue Fever, Healthy Volunteers

  • MezagitamabTAK-079Phase 34 trials

    Takeda · Immune Thrombocytopenic Purpura (ITP), Antibody-Mediated Rejection (AMR), Kidney Disease

  • TAK-360Phase 34 trials

    Takeda · Narcolepsy Type 1, Idiopathic Hypersomnia, Narcolepsy Type 2

  • FazirsiranTAK-999, ARO-AATPhase 33 trials

    Takeda · Alpha1-Antitrypsin Deficiency

  • TAK-755rADAMTS13, recombinant ADAMTS13Phase 33 trials

    Takeda · Thrombotic Thrombocytopenic Purpura (TTP), Acute Ischemic Stroke

  • TAK-771Phase 32 trials

    Takeda · Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP), Multifocal Motor Neuropathy (MMN), Primary Immunodeficiency Diseases (PID)

  • TAK-330Phase 31 trial

    Takeda · Coagulation Disorder

  • TAK-928Phase 31 trial

    Takeda · IO Resistant Squamous and Nonsquamous NSCLC

  • AskBio009BAX 335Phase 21 trial

    Takeda · Hemophilia B

  • HGT-1110Recombinant human arylsulfatase APhase 21 trial

    Takeda · Metachromatic Leukodystrophy (MLD)

  • TAK-007Phase 21 trial

    Takeda · Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)

  • TAK-101Phase 21 trial

    Takeda · Celiac Disease

  • TAK-188Phase 21 trial

    Takeda · Advanced or Metastatic Solid Tumors

  • TAK-341MEDI1341Phase 21 trial

    Takeda · Multiple System Atrophy

  • TAK-411Hypersialylated Immune Globulin GPhase 21 trial

    Takeda · Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

  • TAK-505Phase 21 trial

    Takeda · Malignant Solid Tumors

Recruiting Phase 3 trials

Largest first.

Marketed drugs (40)

Newest FDA action first.

  • Lialda Mesalamine · 2007
  • Pentasa Mesalamine · 1993
  • Mimrylo Rusfertide Acetate · 2026
  • Gattex Kit Teduglutide · 2012
  • Actoplus Met Metformin Hydrochloride, Pioglitazone Hydrochloride · 2005
  • Kazano Alogliptin Benzoate, Metformin Hydrochloride · 2013
  • Orzeyful Oveporexton · 2026
  • Vyvanse Lisdexamfetamine Dimesylate · 2017
  • Vyvanse Lisdexamfetamine Dimesylate · 2007
  • Adderall Xr 10 Amphetamine Aspartate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate · 2001
  • Mydayis Amphetamine Aspartate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate · 2017
  • Entyvio Vedolizumab · 2014
  • Entyvio Vedolizumab · 2023
  • Livtencity Maribavir · 2021
  • Iclusig Ponatinib Hydrochloride · 2012
  • Motegrity Prucalopride Succinate · 2018
  • Fruzaqla Fruquintinib · 2023
  • Fosrenol Lanthanum Carbonate · 2004
  • Fosrenol Lanthanum Carbonate · 2014
  • Vpriv Velaglucerase Alfa · 2010
  • Ninlaro Ixazomib Citrate · 2015
  • Oseni Alogliptin Benzoate, Pioglitazone Hydrochloride · 2013
  • Eohilia Budesonide · 2024
  • Entyvio Vedolizumab · 2024
  • Firazyr Icatibant Acetate · 2011
  • Trintellix Vortioxetine Hydrobromide · 2013
  • Prevacid Lansoprazole · 2002
  • Prevacid Lansoprazole · 1995
  • Nesina Alogliptin Benzoate · 2013
  • Dexilant Dexlansoprazole · 2009
  • Uloric Febuxostat · 2009
  • Carbatrol Carbamazepine · 1997
  • Alunbrig Brigatinib · 2017
  • Velcade Bortezomib · 2003
  • Rozerem Ramelteon · 2005
  • Agrylin Anagrelide Hydrochloride · 1997
  • Intuniv Guanfacine Hydrochloride · 2009
  • Elaprase Idursulfase · 2006
  • Actos Pioglitazone Hydrochloride · 1999
  • Duetact Glimepiride, Pioglitazone Hydrochloride · 2006

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.